By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


NeuroDerm Ltd. 

Ofakim      Israel
Phone: 925-270-0519 Fax: 925-290-1209



Company News
NeuroDerm (NDRM) To Host Second Quarter 2016 Financial Results Conference Call On August 25, 2016 8/11/2016 11:23:49 AM
NeuroDerm (NDRM) Announces Issuance Of A New U.S. Patent For Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions 7/27/2016 8:47:33 AM
NeuroDerm (NDRM) Announces Start Of Bioequivalence Trial In Healthy Volunteers Of ND0701, A New Continuous Subcutaneously Delivered Apomorphine Product Candidate For The Treatment Of Advanced Parkinson’s Disease 7/26/2016 8:38:14 AM
NeuroDerm (NDRM) To Present At The Cantor Fitzgerald Healthcare Conference On July 13 7/5/2016 8:47:23 AM
NeuroDerm (NDRM) Announces Start Of U.S. Patient Enrollment In Trial 006, A Phase II Trial Of ND0612H For Advanced Parkinson’s Disease 7/1/2016 12:12:35 PM
NeuroDerm (NDRM) Announces ND0612H Achieves Comparable Pharmacokinetics To DUODOPA In Head-To-Head Pilot PK Comparison Trial 6/29/2016 11:50:25 AM
NeuroDerm (NDRM) Announces Patient Enrollment In Long-Term Safety Trial Of ND0612 For Parkinson’s Disease 5/9/2016 1:14:00 PM
NeuroDerm (NDRM) Announces 2016 Annual General Meeting Of Shareholders 5/5/2016 10:46:46 AM
Good News for NeuroDerm (NDRM) as the FDA Removes Import Alert of Infusion Pumps Used in ND0612 Clinical Trials 4/22/2016 7:58:01 AM
NeuroDerm (NDRM) To Host Fourth Quarter And 2015 Fiscal Year Financial Results Conference Call On March 31, 2016 3/22/2016 8:13:50 AM